Document is current
Any future updates will be listed below
-
Authors
Osterlund, Emerik
Hammarström, Klara
Nunes, Luís
Mathot, Lucy
Mezheyeuski, Artur
Sjöblom, Tobias
Glimelius, Bengt
-
Funding
Funding for this research was provided by:
Lions Cancerforskningsfond Mellansverige
Cancerfonden (22 2054 Pj 01H)
Amgen
- License Information
-
More Information
Article History
Received: 16 December 2024
Revised: 4 May 2025
Accepted: 13 May 2025
First Online: 28 May 2025
Competing interests
: EO has been on an advisory board for Amgen, received lecture honoraria from Amgen, and travel reimbursements from Amgen, Merck KGaA, and Nordic Drugs. LN was employed by Oncodia AB at the time of the study. TS is co-founder and shareholder of Oncodia AB. BG has received an unrestricted research grant from Amgen. No other authors report any conflicts of interest.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Review Board at Uppsala University (2010-198-0, 2015/419 and 2018/490). The patients included in the Uppsala-Umeå Comprehensive Cancer Consortium provided written informed consent, whereas the Swedish Colorectal Cancer Registry works with an opt-out principle.
